[-] Show simple item record

dc.contributor.authorWong, Longeng
dc.contributor.authorCriswell, Daneng
dc.date.issued2009-12eng
dc.description.abstractNo data are available to support the addition or substitution of warfarin after failure of antiplatelet agents for secondary prevention of ischemic stroke. Further, warfarin may be no better than placebo at reducing the risk of noncardioembolic stroke. (Strength of recommendation [SOR] B, based on heterogeneous meta-analyses.)eng
dc.identifier.citationEvidence Based Practice 12(12): 01-02.eng
dc.identifier.urihttp://hdl.handle.net/10355/7655eng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofEvidence Based Practice 12(12): 01-02.eng
dc.relation.ispartofcollectionEvidence Based Practice, 2009eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network. Evidence Based Practice.eng
dc.subjectthrombotic occlusioneng
dc.subjectaspirin therapyeng
dc.subject.lcshThrombosiseng
dc.subject.lcshAspirin -- Therapeutic useeng
dc.titleWarfarin therapy not warranted for secondary prevention of CVDeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record